NK Cell Therapy Enhanced with IL-15 for Advanced Solid Tumors
Part of Cancer clinical trials.
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- A confirmed solid tumor (breast, liver, lung, etc.) that has spread or returned despite prior treatment
- At least one tumor that can be measured on imaging scans
- Healthy enough bone marrow, liver, kidney, and blood clotting function
- Fully recovered from side effects of any previous cancer treatments
- Willing to sign informed consent and understand the experimental nature of the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests a new immune cell therapy called NK521 for people with advanced solid tumors like liver or ovarian cancer that have not responded to standard treatment. The therapy may be given as an infusion or into the belly (for those with fluid buildup containing cancer cells).
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.